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AN OVERVIEW OF THE DISEASE MODEL FOR DRUG ADDICTION AND 
INTERVENTIONS USED TO ADDRESS THE CURRENT OPIOID EPIDEMIC 
 
KITAE CHANG 
 
ABSTRACT 
America is engulfed in an opioid epidemic. Whether this is depicted through the 
tens of thousands of lives claimed by the number of drug overdoses each year, the 
unprecedentedly high and increasing rates of opiate abuse, or the broadening 
demographic profile of the addict, it is clear that the current issue is one that requires 
serious attention. As informed by the negative attitudes toward drug addiction that have 
prevailed since the War on Drugs was declared, it is hypothesized that much of the 
contemporary predicament is a result of this misinformation that did not resolve, but 
exacerbated the drug crisis. Despite the concurrent emergence of evidence asserting that 
addiction is a disease, instead, the idea that drug addiction is a failure prevails.  
As with many brain diseases, drug addiction displays both pathological alterations 
in the transmission of signals within the neural circuitries and the morphological defects 
associated with non-random regions of the brain. The alteration that is observed during 
opioid tolerance is the desensitization of mu opioid receptors to dopamine, resulting in 
the need of increased dosage of opiates to achieve the same high. During opioid 
dependence, key changes that are seen in the locus ceruleus and the mesolimbic reward 
system increase both the likelihood of an overdose event and withdrawal when an 
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exogenous opioid is present or absent, respectively. There are two models that describe 
additional changes that occur during the transition from frequent abuse to addiction: (1) 
the “Changed Set Point Model” and (2) the “Cognitive Deficits Model.” All three 
variants of the “Changed Set Point Model” portray a shift in the physiological set points 
of dopamine and glutamate levels in the reward system and regions that control it. The 
“Cognitive Deficits Model” theorizes that the modifications localized to the prefrontal 
cortex are responsible for the ultimate transition. 
Once the abuser is thrust into the addiction cycle, additional changes in the neural 
networks are observed. These changes are seen in each of the three phases: (1) Binge and 
Intoxication, (2) Withdrawal and Negative Affect, and (3) Preoccupation and 
Anticipation. In the first phase, a process called drug-induced neuroplasticity occurs, 
resulting in the amplification of signals originating from dopaminergic neurons. Next, 
during Withdrawal and Negative Affect phase, among other changes, the amygdala is 
shown to be re-wired in such a way that the addict is more sensitive to stress. And finally 
in the last phase, the changes that occur, secondary to processes similar to drug-induced, 
are indicated in the prefrontal cortex. 
The current FDA-approved medication-assisted therapies include methadone, 
buprenorphine, and naltrexone. The single outstanding abstinence-based treatment is the 
12-step program. In the evaluation of medical and non-medical interventions the relative 
efficacies were measured using the metrics: (1) rates of abstinence achievement, (2) rates 
of opioid use, and (3) retention in treatment. Individually, all therapies show moderate 
success when measured against each metric, which further validates the brain disease 
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model for addiction, and also indicates that the future direction of addressing the opioid 
epidemic should point at combination therapies. What is most imperative now is for there 
to be more widespread recognition of the brain disease model for addiction. 
 
  
  viii 
TABLE OF CONTENTS 
 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER’S APPROVAL PAGE………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES ........................................................................................................... xi 
ABBREVIATIONS ......................................................................................................... xiii 
INTRODUCTION .............................................................................................................. 1 
The Current Scene .................................................................................................... 2 
The War on Drugs: Saying No to a Brain Disease Model for Addiction ............. 9 
Brain Disease Model for Addiction ....................................................................... 12 
SPECIFIC AIMS .............................................................................................................. 30 
INTERVENTIONS TO CURB THE OPIOID EPIDEMIC ............................................. 31 
EVALUATION OF THE INTERVENTIONS ................................................................. 45 
Evaluation of Medication Assisted Therapy as Treatment for Drug Addiction 46 
  ix 
Evaluation of Abstinence-based Therapy for Drug Addiction ........................... 60 
CONCLUSION - THE VALIDITY OF THE BRAIN DISEASE MODEL FOR DRUG 
ADDICTION .................................................................................................................... 67 
APPENDIX I – DRUG OVERDOSE DEATHS PER STATE ........................................ 69 
REFERENCES ................................................................................................................. 70 
CURRICULUM VITAE ................................................................................................... 82 
 
  
  x 
LIST OF TABLES 
 
 
Table Title Page 
1 Number and Age-adjusted Rates of Drug Poisoning 
Deaths Involving Analgesics and Heroin: United States, 
2000-2014. 
3 
2 Definitions of Key Terms 17 
3 Definitions 27 
4 Processes Associated with the PFC that are Disrupted in 
Addiction 
32 
5 Characteristics of Medications for Opioid-Addiction 
Treatment 
36 
6 Total and Specific [
18
F]cyclofoxy Binding in Different 
Brain Regions 
39 
7 12 Concepts for Narcotics Anonymous Service 47 
8 Outcome Measures of LAAM, Buprenorphine, and 
Methadone Based Maintenance Programs 
51 
9 Clinical Outcomes of XR-NTX 54 
10 Forest Plot of Comparison: Flexible Dose Buprenorphine 
vs. Flexible Dose Methadone; Retention in Treatment 
61 
11 Prediction of Abstinence at Eight Years 65 
 
  xi 
LIST OF FIGURES 
 
 
Figure Title Page 
1 Age-adjusted Rates of Death Related to Prescription 
Opioids and Heroin Drug Poisoning in the United States, 
2000-2014 
3 
2 Past Month Nonmedical Use of Types of 
Psychotherapeutic Drugs among Persons Aged 12 or 
Older: 2002-2013 
5 
3 Past Month and Past Year Heroin Use among Persons 
Aged 12 or Older: 2002-2013 
6 
4 Deaths from Drug Overdose Across Different Ethnicities 
in the United States, 1999-2014 
7 
5 Prescription Painkiller Sales and Deaths in the United 
States, 1999 - 2013 
8 
6 Number of People in Federal Prison for Drug Offenses, 
1980-2014 
10 
7 The Mesolimbic Reward System  14 
8 The Neurological Basis of Dependence and Withdrawal at 
the Cellular Level 
17 
9 Stages of the Addiction Cycle 22 
10 The Buffering Effect of Methadone on Heroin Use 33 
  xii 
11 Specific Binding of [
18
F]cyclofoxy in Various Brain 
Regions of Patients that Did or Did Not Receive 
Methadone Treatment 
35 
12 The Ceiling Effect of Buprenorphine 37 
13 Time Course of Plasma Levels of Buprenorphine and 
Naloxone after Administration of Sublingual Suboxone 
39 
14 Oral Naltrexone Refills, 2000-2002 41 
15 States that Provides Medicaid Coverage for Methadone, 
Buprenorphine, and Naloxone 
45 
16 Time Course of Changes in Opiate Craving 49 
17 Change in Craving During the Course of Treatment with 
Vivitrol vs. Placebo 
51 
18 Pooled Effects of Various Drug Conditions in Comparison 
with High Dose Methadone on Prevention of Illicit Opioid 
Use 
53 
19 Percentage of Urine Samples Negative for Opioids (With 
Cocaine + Benzodiazepines) Through the Duration of 
Treatment with Suboxone 
55 
20 Proportion of Opioid-Free Participants in XR-NTX 
Treatment vs. Placebo 
56 
21 Retention in Treatment by Study Week and Dose-
Dependent Treatment Group 
60 
  xiii 
ABBREVIATIONS 
 
ACA ...................................................................................................... Affordable Care Act 
AMPA .......................................... α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BNST ..................................................................................... Bed Nucleus Stria Terminalis 
DA ......................................................................................................................... Dopamine 
DAWN ................................................................................. Drug Abuse Warning Network 
DEA ........................................................................................... Drug Enforcement Agency 
FDA...................................................................................... Food and Drug Administration 
GABA ........................................................................................Gamma-amino butyric acid 
LAAM ........................................................................................Levo-alpha-acetylmethadol 
LC .................................................................................................................Locus Ceruleus 
MAT ..................................................................................... Medication Assisted Therapies 
MHPAEA ................................................... Mental Health Parity and Addiction Equity Act 
NA ................................................................................................................... Noradrenaline 
NAc .......................................................................................................Nucleus Accumbens 
NIDA................................................................................ National Institute on Drug Abuse 
NMDA ............................................................................................... N-methyl-D-aspartate 
NSDUH ................................................................National Survey on Drug Use and Health 
ORL1................................................................................................. Opioid-like Receptor 1 
PET ..................................................................................... Positron Emission Tomography 
PFC ............................................................................................................ Prefrontal Cortex 
  xiv 
VTA ................................................................................................ Ventral Tegmental Area 
XR-NTX ................................................................................ Extended Release Naltrexone 
 
 
 
  
 1 
INTRODUCTION 
 
This thesis has been organized with a specific chronology in mind. While the bulk 
of the text is devoted to laying out the current understanding of drug addiction as a 
disease of the brain, a substantial portion of the following introduction will lay down the 
context, both in the current and past fabric, for drug addiction in the United States. This 
task will first require observing the statistics that govern the current times followed by 
delving briefly into the recent history of drugs in this country to highlight remarkable 
events that have shaped the present circumstances.   
It is beyond the scope of this thesis to conduct a comprehensive review of the 
underlying causes of addictive behaviors since it would be impossible to do so without 
detracting from the larger goal of this thesis, which is to validate the brain disease model 
for addiction. Instead, the discussion portion will evaluate various interventions, which 
either do or do not treat addiction as a brain disease.  
Also it is worth mentioning here that in the interest of bringing focus to the thesis, 
the all-encompassing general term, “drug addiction issue,” and phrases of equivalent 
meaning will henceforth exclusively be referring to opioids, unless otherwise stated. This 
adjustment is being made in recognition of the notable impact of the opioid class of drugs, 
including heroin, on the contemporary epidemic. And as will be alluded to shortly, pain 
analgesics and heroin are the main drivers of the modern surge in drug-related deaths. 
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The Current Scene 
 It is often regarded that obesity is this generation’s primary medical and public 
health challenge. Especially when one considers the magnitude of the problem by size, 
with more than one-third of American adults and roughly 17% of the youth population 
classified as obese, it is of no surprise to observe the vast efforts that have been put forth 
to control and thwart the epidemic (Ogden et al., 2014). However, the drug addiction 
crisis is deserving of just as much attention given its unprecedented prevalence in modern 
day America. In 2014, 47,055 lives, which translate to roughly 0.01% of the United 
States population, were lost due to drug overdoses (Rudd et al., 2016). While this number 
starkly pales in comparison to the obese population by sheer size, it belies the startling 
fact of how quickly the problem is growing; from 2000 to 2014, the overall rate of death 
due to drug overdoses increased by 137% (Rudd et al., 2016; Table 1). These rates 
already eclipse the number of people who die from automobile accidents (Wilson, 2013). 
A closer look at the numbers in Table 1, and the corresponding plot portrayed in Figure 
1, reveals that among all drug overdoses, those related to opioids, namely heroin and pain 
analgesics, have driven the surge since 2000. From the period spanning from 1999 to 
2014, the rates of death due to opioid analgesics and heroin increased by 469% and 539%, 
respectively. These measures of drug impact not only reflect the challenge in treating 
drug addiction patients, but also imply the obstacles of preventing drug overdose deaths. 
As will be discussed in later sections, there currently exist medical interventions that can 
reverse the effects of opioid overdose.  
 3 
Table 1. Number and Age-adjusted Rates of Drug Poisoning Deaths Involving 
Analgesics and Heroin: United States, 1999-2014. Figure taken from CDC/NCHS, 
National Vital Statistics, Mortality File 2014.  
 
 
 
 
 
Figure 1. Age-adjusted Rates of Death Related to Prescription Opioids and Heroin 
Drug Poisoning in the United States, 2000-2014. The data used to depict the trends for 
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Prescription Opioids have been adopted from the CDC/NCHS, National Vital Statistics, 
Mortality File 2014 (See Table 1). Figure taken from (Compton et al., 2016). 
 
According to the 2013 National Survey on Drug Use and Health (NSDUH), the 
primary source of information regarding the use of illicit drugs, alcohol, and tobacco, the 
levels of non-medical use of pain relievers and heroin have remained more or less stable 
from 2002 to 2013 (Substance Abuse and Mental Health Services, 2014; Figure 2; 
Figure 3). It seems reasonable to think that if drug overdose related deaths were to 
remain at levels previously observed with no significant increase in the number of opioid 
drug abusers, a moderate response could significantly curtail the number of deaths. 
However, this seems unlikely when considering that other indications suggest otherwise. 
The opioid drug usage is also growing at unprecedentedly high rates. In the Drug Abuse 
Warning Network’s (DAWN) reports on drug-related emergency department visits, the 
data showed that the time span from 2004 to 2011 a 153% surge in emergency 
department visits related to misuse or abuse of prescription opioids. A more than 
quadrupling of the rate of hospital admissions due to prescription-opioid overdose was 
also reported between 2002 and 2012 (Substance Abuse and Mental Health Services 
Administration, 2013; Substance Abuse and Mental Health Services Administration, 
2014). This discrepancy, while putting to question the severity of America’s drug 
problem, also inadvertently shows the nature of drug addiction. That is, drugs are most 
commonly abused in private. So much so that even the numbers of self-proclaimed 
abusers of opioids and overdosed patients who end up in ERs are most likely not 
commensurate with the actual severity of the drug epidemic. Many excluded from these 
 5 
counts are those who time and time again narrowly escape their death. And these 
individuals - or “hungry ghosts”, as physician Dr. Gabor Maté refers to them - are found 
in all corners of society and blend with the rest of the populous (Maté, 2010). Whereas an 
untrained eye can spot the obese, even the trained eye cannot easily identify the addict. 
 
 
Figure 2. Past Month Nonmedical Use of Types of Psychotherapeutic Drugs among 
Persons Aged 12 or Older: 2002-2013. The levels of self-reported abuse of pain 
relievers have remained steady for the last decade. Figure taken from 2013 National 
Survey on Drug Use and Health. 
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Figure 3. Past Month and Past Year Heroin Use among Persons Aged 12 or Older: 
2002-2013. Figure taken from 2013 National Survey on Drug Use and Health. There has 
been a generally consistent increase in the reported usage of Heroin in the last decade. 
 
While there are some parallels to be drawn between each epidemic, there are 
certainly some notable differences that stand in the way of juxtaposing these two crises. 
And if anything, such differences may provide more reasons for also bringing the drug 
addiction issue to the forefront of nationwide concerns.  
For one, the drug epidemic has displayed its unique versatility over the last few 
decades, which has added to the overall complexity of containing its spread. Drugs are 
now crossing demographic boundaries (Kolata & Cohen, 2016). In the 1960s and 1970s, 
heroin abuse and addiction were issues that were confined to young men from minority 
groups living in urban areas (Dupont, 1971; Greene, 1974). By numbers, some studies 
have reported that among those who began using heroin in the 1960s, approximately 82.8% 
were males of minority groups, most commonly those of African American and Hispanic 
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descent (Cicero et al., 2014). Today, heroin use is itself most prevalent among 
Caucasians, including those of affluent status (Figure 4).  
 
 
 
Figure 4. Deaths from Drug Overdose Across Different Ethnicities in the United 
States, 1999-2014. Figure taken from (Kolata & Cohen, 2016).   
 
Interestingly, studies have traced this most recent change in the demographics of 
the heroin problem to the initiation through prescription opioid abuse (Unick et al., 2013; 
Lankenau et al., 2012). The main reason for this switch is cited to be due to costs and 
barriers to accessing prescription pain relievers (Cicero et al., 2014). Furthermore, some 
correlative reports have pinned the increase in opioid abuse to concomitant increases in 
prescribing of opioid analgesics, with opioid pain reliever sales quadrupling between 
1999 and 2010 (Paulozzi et al., 2011; Figure 5). Put another way, it seems as though the 
healthcare system is partly responsible for the exacerbating the burgeoning issue; this is 
something unseen in the obesity problem. 
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Figure 5. Prescription Painkiller Sales and Deaths in the United States, 1999 - 2013. 
Figure taken from the CDC, National Vital Statistics System mortality data (2015). 
  
However, despite all the distinguishing features between the two epidemics, the 
most outstanding difference is the status of the fight against each problem. Whereas no 
significant changes in obesity prevalence in youth or adults were observed from 2003-
2004 to 2011-2012, in the same window of time, the number of deaths related to drug 
overdoses soared from 27,424 in the 2003-2004 period to 41,502 in the years 2011-2012, 
approximately a 51% increase (Ogden et al., 2014; Rudd et al., 2016; Table 1). Put into 
words, the great advances that have been made in combating obesity in recent years is 
seen to a lesser extent in the drug epidemic.  
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The War on Drugs: Saying No to a Brain Disease Model for Addiction 
 
In the not so distant future, it may be difficult to imagine a time in which drug 
addiction was not viewed as a disease, but instead, a willful behavior driven by moral 
turpitude. Today, however, despite the emergence of overwhelming amounts of scientific 
evidence which depict the chronic disease-like symptoms displayed by drug addiction 
along with the pathological changes of the neural circuitries in the addict’s brain, there is 
still a paradigm that treats drug addiction as a form of moral failing or a criminal 
behavior. The origins of this view can be traced to the middle of the 20
th
 century, when 
drug addiction was an issue that was most prevalently found in minority and low 
socioeconomic status communities. It was during a period of American history, at the 
peak of racial tensions that President Nixon declared the “War on Drugs” in June of 1971 
(drugpolicy.org, n.d.). Prior to the declaration of the “war on drugs,” in fact a very small 
fraction of the American public, approximately two percent, saw drugs as an important 
issue facing the country (Beckett, 1997).  
Notwithstanding this fact, President Nixon and successors were not deterred from 
engaging in the war (Alexander, 2012). From the early 1980’s to the 1990’s, funding for 
the FBI anti-drug initiative soared from $8 million dollars to $95 million dollars, just as 
allocations for the Department of Defense’s programs for anti-drug hunts were also 
increased by over three thousand percent from $33 million to $1.042 billion dollars 
(Beckett, 1997). Following suit, the Drug Enforcement Agency’s (DEA) spending grew 
from $86 million to $1.026 billion (Office of National Drug Policy, 1992). In contrast, 
funding for groups like the National Institute on Drug Abuse (NIDA) and the Department 
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of Education, agencies that worked to improve drug treatment, prevention and education 
were truncated by nearly the same proportions by which drug criminalizing agencies’ 
budgets were expanded (Beckett, 1997). During this time period, the primary means by 
which the nation addressed drug addiction was not through treatment, but rather through 
policing. Consequently, while the full-fledged “war on drugs” instead gave birth to mass 
incarceration (Figure 6). 
 
 
Figure 6. Number of People in Federal Prison for Drug Offenses, 1980-2014. Figure 
taken from The Sentencing Project (2015). As evident, convictions for drug offenses are 
the main cause of the sudden explosion in the prison population in recent history. 
 
 
At a time when the earliest identifications of pathological morphologies of 
addicted brains were being made, the push to jail drug offenders gave rise to a sentiment 
that equated drug usage with criminal activity. Seminal studies in medicine and public 
health that went against the grain of dominating views by drawing ties between drug 
abuse, poverty, and failed school systems were ignored (Provine, 2007). Instead, the 
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major media outlets echoed and reinforced the criminalization of drug addicts (Alexander, 
2012). As the movement gained traction, the government passed legislations that have 
made it more difficult for addicts to obtain treatment or help of any kind. The Anti-Drug 
Abuse Act of 1986 along with its amended version in 1988 included the elimination of 
several federal benefits – including healthcare – for drug-related criminals (Wright, 1987).  
 Despite its intent to curb the early surge in drug addiction, the “war on drugs” has 
had detrimental effects on society. As suggested by the current situation, the issue has 
grown in size since the drug epidemic no longer just plagues the inner city streets of 
urban, under-resourced areas, but nearly all factions of society. It has also shifted from 
being an issue primarily belonging to minorities to one that is colorblind (Figure 3). 
Further, as with all wars, the “war on drugs” was not without casualties: those who still 
remain behind bars and those who have died from having been barred from treatment and 
support. As society has opted to see drug addiction as a crime as opposed to a disease, 
what remains to be true is the fact there are thousands upon millions of addicts who are 
not receiving the care and treatment they require. While the 21st century has hinted at 
shifts in the attitude toward drug addiction, with the sprouting of treatment centers and 
the granting of presidential clemency for 46 mild-drug offenders, much remains to be 
done (Nelson & Tau, 2015).   
Although a growing portion of American society no longer views drug addiction 
as previously understood, there is a good reason why residues of the former ideas still 
exists in the current fabric. As described by Longo et al. (2016):  
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“The concept of addiction as a disease of the brain challenges deeply ingrained 
values about self-determination and personal responsibility that frame drug use as 
a voluntary, hedonistic act. In this view, addiction results from the repetition of 
voluntary behaviors. How, then, can it be the result of a disease process? (p. 364)”  
 
Furthermore, those skeptical of the disease model have also argued that such thinking can 
act to excuse the addict and addict-potential from possessing any responsibility for 
actions and also lay grounds for justifying continuation and initiation of illicit drug use.  
 While these are reasonable counterarguments, the upcoming review of scientific 
literature will show that great advances have been made in elucidating the interruptions in 
the emotional balance and decision-making ability of addicts that have bolstered the brain 
disease model for addiction.    
  
Brain Disease Model for Addiction 
 In an effort to organize the discussion on the disease model for addiction, this 
section will be laid out by looking at the phases of the addiction cycle: Binge and 
Intoxication, Withdrawal and Negative Affect, and Preoccupation and Anticipation. 
Using the different phases as a backbone, the correlative disruptions in the neural 
circuitries will be explored. However, before looking at the pathological implications of 
drug addiction on the brain, it is of interest to understand the actions of opiates on the 
brain and the steps stages that generally precede addiction – opioid tolerance, 
dependence, and withdrawal. For referencing purposes, a glossary of terms related to 
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opioid neurobiology, adapted from Kosten and George’s study (2002), has been included 
below (Table 2): 
 
Table 2. Definitions of Key Terms. Adapted from (Kosten & George, 2002). 
Dopamine (DA) A neurotransmitter present in brain regions that regulate 
movement, emotion, motivation, and the feeling of pleasure. 
Gamma-amino butyric 
acid (GABA) 
A neurotransmitter in the brain whose primary function is to 
inhibit the firing of neurons. 
Locus ceruleus (LC) A region of the brain that receives and processes sensory 
signals from all areas of the body; involved in arousal and 
vigilance. 
Noradrenaline (NA) A neurotransmitter produced in the brain and peripheral 
nervous system; involved in arousal and regulation of blood 
pressure, sleep, and mood; also called norepinephrine. 
Nucleus accumbens 
(NAc) 
A structure in the forebrain that plays an important part in 
dopamine release and stimulant action; one of the brain’s key 
pleasure centers. 
Prefrontal cortex (PFC) The front-most part of the brain; involved in higher cognitive 
functions, including foresight and planning. 
Ventral tegmental area 
(VTA) 
The group of dopamine-containing neurons that make up a key 
part of the brain reward system; key targets of these neurons 
include the nucleus accumbens and the prefrontal cortex. 
 
 
 
 
Neurobiology of Opioid Use 
 The euphoric episodes or the feelings of pleasure that are commonly associated 
with opioids are result of an opiate entering the brain through the bloodstream and 
binding to mu opioid receptors in the brain. The key neuro-circuitry involved in this 
process is called the mesolimbic reward system that is localized to the midbrain region 
(Figure 7). Specifically within the reward system is a region called the ventral tegmental 
area (VTA), in which the signals for the release of the neurotransmitter dopamine (DA), 
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into another compartment of the brain called the nucleus accumbens (NAc), originates 
(Kosten & George, 2002). It is the release of DA into the NAc that is actually responsible 
for the feelings of pleasure.  
 
 
Figure 7. The Mesolimbic Reward System. VTA – Ventral Tegmental Area; NAc – 
Nucleus Accumbens; LC – Locus Cerelus: plays an important role in drug dependence; 
PFC – Prefrontal Cortex: feeds back to the VTA to control pleasure seeking that may be 
deleterious; Figure taken from (Kosten & George, 2002). 
 
 
 
 Even prior to developing an addiction, the early stages of opioid abuse, is marked 
by a drive for repeated use due to the stimulation of mesolimbic reward system and the 
subsequent sensations caused by dopamine release. However, gradually a compulsivity to 
seek opioid use – which transcends just a craving for the pleasure – develops, and a 
greater dosage of opioid is required to satiate the compulsion (Sinatra et al., 2011). This 
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phenomenon of needing greater doses of an opioid to reach the elated state is referred to 
as opioid tolerance. It occurs due to the mu receptors losing their responsiveness to the 
opiate ligand. The compensatory means by which the same level of dopamine release in 
the NAc can be achieved is by saturating the receptors with even higher concentrations of 
the opioid (Dean et al., 2009).  
Opioid dependence, which is a state in which the body is physically reliant upon a 
hit of opioids to maintain baseline conditions, occurs due to alterations that are located in 
a region of the brain called the locus ceruleus (LC) (Strain & Stitzer, 2006; Figure 7; 
Figure 8). While other changes have been recorded to take place even in the mesolimbic 
reward system due to the reduced secretions of DA following opioid tolerance, such as 
the inability to experience pleasures from previously enjoyable activities, the primary site 
of modifications that lead to the onset of withdrawal symptoms is known to be localized 
to the LC. In the absence of opioids, a neurotransmitter called noradrenaline (NA) is 
produced by neurons of the LC. NA is a versatile compound that is active in various 
compartments of the brain and its downstream actions include, but are not limited to, 
stimulation of attentiveness, increasing respiration, and raising of the blood pressure 
(Kosten & George, 2002).  However, in the presence of opioids, the mu receptors of the 
LC are bound, and consequently, NA is unreleased causing respiratory depression, 
tiredness, and a lowering of blood pressure. Interestingly, as occurs during the early 
phase of abuse, when the frequency of dosage of opioid use increases, the LC 
concordantly adapts by shifting to a more hyperactive gear; more NA is pumped. This 
adjustment allows for the brain to continue streaming NA in the face of opioid presence, 
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in effect, offsetting the suppressive effects which would ultimately be detrimental to the 
user. Therefore, a physical dependence is established; if opioids are not used, then the LC 
produces a surplus of NA that causes overstimulated responses including passing of 
looser stool, feelings of anxiety, and cramping of muscles, which are the commonly 
identified symptoms of opioid withdrawal (Wikler, 1980). Importantly, this means that 
for most drug users, the transition of opioid use into addiction is impelled by a need to 
mitigate undesirable withdrawal symptoms. While the impulse to use is not as strong 
earlier on, as dependence grows, the imminent addicted stage is framed by longer-lasting 
changes in the brain that shifts impulsive use of opioids to one that is driven from 
compulsion (Table 2). Currently, there exist two models that account for the neural 
changes that fuel the transition into addiction: (1) the “Changed Set Point Model” and (2) 
the “Cognitive Deficits Model.” 
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Figure 8. The Neurological Basis of 
Dependence and Withdrawal at the 
Cellular Level. Figure adapted from 
(Kosten & George, 2012). 
 
A. Prior to exposure to opioid drugs, 
baseline levels of NA are maintained 
through endogenous opioid compounds 
like endorphins. When such chemicals 
bind to the mu receptor, they cause a 
cascade which leads to the formation of 
a signaling compound called cyclic 
adenosine triphosphate (cAMP) that 
causes NA to be released. These normal 
levels of DA maintain important 
functions such as respiration and 
muscle tone.  
 
B. When an exogenous opioid binds to 
the mu receptor, the enzyme that 
produces cAMP is inhibited, and 
consequently, NA levels decrease. 
Overdose-like symptoms arise. 
 
C. As the frequency of opioid abuse 
increases, the neuron raises the amount 
of enzyme and ATP molecules, thereby 
generating more cAMP to compensate 
for the increased inhibition conferred 
by higher levels of exogenous opiates. 
This way the neuron can maintain 
roughly the same level of NA. 
 
D. When the exogenous supply is 
stopped, the inhibition is lost and 
therefore even higher levels of NA are 
produced since the neuron had made 
offsetting adjustments. The effect of 
this is the onset of withdrawal 
symptoms.  
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The Changed Set Point Model for Transition into Addiction 
 There are three closely related variations of the “Changed Set Point” model, but 
all have in common the theme that prolonged opioid use shifts physiological set points in 
the brain, namely in the neurons of the mesolimbic reward system and the LC. 
 The first version is premised on the assumption that VTA neurons are innately 
preset to secrete an adequate amount of dopamine into the NAc in the face of regularly 
experienced pleasures, such as eating (Koob & LeMoal, 2001). Given the previously 
described effects of opioids in the VTA and the LC, repeated usage of these drugs is 
asserted to induce cycles of natural set point alterations in each region that in effect 
thwart the normal flux of DA in response to rewarding stimuli and excessively promote 
the release of NA. These inversely directed neuronal changes offer explanations for the 
phases of drug craving (negative reinforcement) and withdrawal seen in drug addiction. 
 The second variant, offered by the studies of Grace (2002), contends that the 
transition into addiction is driven largely by a set point change that occurs exclusively in 
the mesolimbic reward pathway. Specifically, the neurons of the VTA that release DA 
are rendered incapable of releasing normal amounts of DA under baseline conditions. 
Although there are several factors that regulate the concentration of DA secreted, as it 
pertains to this model, the two antagonistic components that go awry are the glutamate-
releasing neurons – also known as the cortical excitatory neurons – which stimulate VTA 
neurons to secrete DA, and the autoreceptors that feedback inhibits the VTA neurons 
when there is an overabundance of DA in the NAc (Grace, 2002). In the same way that 
the LC adjusts to higher levels of opioids, as occurs during frequent opioid usage, the 
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study showed that autoreceptors purportedly become constitutively hyperactive upon 
incessant exposure to heroin and commonly used pain analgesics. As consequences of 
this new state of autoreceptor activity, in the absence of opioids, the new baseline levels 
of DA release by VTA neurons were recorded to be much lower and withdrawal 
symptoms ensued (Grace, 2002). In response, the addict compulsively takes more opioids 
to subdue or escape from withdrawal. And once more, when the pleasurable feelings 
whittle, the cycle re-begins. 
 Even in the absence of opioids, unlike the scenarios described in the previous two 
models, the mere craving for opioids can lead to changes in the biological set points. The 
third hypothesized model puts emphasis on the fact the brain is wired to recall the 
euphoric pleasantries associated with an opioid, and thus just the wanting or hunger for 
the drug can correspond to the surge of glutamate levels, which subsequently raises the 
baseline concentrations of DA in the NAc (Robinson & Berridge, 2000). This induces a 
vicious cycle because the usage of the drug, as explained earlier, also raises glutamate 
levels, which in effect also raises the activity of DA secreting neurons and thereby causes 
the craving feelings to recur even despite having already satiated the original hunger 
(Breiter et al., 1997). Thus, in this last version of the “Changed Set Point Model,” the 
frequent user of opioids is thrust into the addiction cycle through intrinsic changes that 
occur primarily in the elements that responds to anticipations and cravings, namely, the 
cortical excitatory neurons. 
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The Cognitive Deficits Model for Transition into Addiction 
 Unlike the “Changed Set Point Model,” the “Cognitive Deficits Model” points to 
derangements in a completely different region of the brain: the prefrontal cortex (PFC) 
(Figure 8). As is described in Table 2, the PFC has the overarching role of executive 
command. That is, the PFC controls humans’ abilities to judge and plan, which are 
cognitive abilities crucial for selecting choices that have long-term rewards in lieu of 
impulses for instant gratification, such as adverse drug use (Fuster, 2009). At the 
biological level, this occurs via inhibitory signals that are forwarded by the PFC to the 
neurons of the VTA, resulting in the attenuation of DA release (Kosten & George, 2002). 
In the transition from overuse of opioids to addiction, the PFC-mesolimbic reward system 
communication becomes distorted in such a way that the controls for judgment and 
decisions to forgo the impulses for drug usage are lost. This alteration has been verified 
even in the context of alcohol addiction, in which the levels of gamma-amino butyric acid 
(GABA) are pathologically low (Behar et al., 1999). GABA is a neurotransmitter that is 
secreted by the PFC to decrease secretion of DA in the VTA. Furthermore, studies have 
shown that in disorders associated strictly with PFC abnormalities, such as antisocial 
personality disorder, there is a higher propensity for developing opioid addiction (Raine 
et al., 2000). 
 Most likely, the gradual transition into addiction is caused by a combination of all 
of the aforementioned models and variants. In the shift from opioid abuse to opioid 
addiction, several changes involving multiple regions of the brain have been observed. 
And on top of these adjustments, during the addiction cycle even more components of 
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brain become defunct.  Without proper intervention, what begins as transient changes will 
gradually transform into ones that become increasingly difficult to reverse. 
 
The Addiction Cycle    
It is generally understood that addiction is composed of three phases, namely the 
Binge and Intoxication Phase, the Withdrawal and Negative Affect Phase, and the 
Preoccupation and Anticipation Phase. Each part of the cycle is associated with the 
activation of a region of the brain as shown below with corresponding colors (Figure 9). 
Just as in the previous subsection, a list of terms and their definitions have been 
appropriately defined in Table 3 to fit the context of the following discussion. 
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Figure 9. Stages of the Addiction Cycle. Binge and intoxication phase (blue): when 
drug use occurs, the correspondingly colored regions – the reward systems – of the brain 
are activated. Preoccupation and anticipation (green): there is decreased inhibition by the 
PFC, which triggers the compulsive motivation for drug use; relapse occurs and the cycle 
is reinitiated. As can be seen above, there is a strong interplay between this region and the 
components shaded in green, which represent the areas that are areas that become 
sensitized to conditioned cues. Withdrawal and negative affect (red): when withdrawal 
occurs due to increased levels of NA, the regions in red are activated and negative mood 
and increased sensitivity to stress result. Figure taken from (Longo et al., 2016).  
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Table 3. Definitions. Adapted from (Koob & Volkow, 2010). 
 
 
Addiction 
Assumed to be identical to the syndrome of Substance Dependence (as 
currently defined by Diagnostic and Statistical Manual of Mental 
Disorders; American Psychiatric Association, 1994), and Substance 
Dependence on Alcohol is assumed to be identical to alcoholism. The 
term “addiction” is favored over dependence to avoid confusion with 
“physical dependence,” which refers to the physical adaptations that 
result in largely somatic withdrawal symptoms when drugs such as 
alcohol, heroin, and benzodiazepines are abruptly discontinued. The 
adaptations associated with physical drug withdrawal are distinct from 
the motivational changes of acute withdrawal and protracted 
abstinence. 
Impulsivity 
Defined behaviorally as ‘a predisposition toward rapid, unplanned 
reactions to internal and external stimuli without regard for the 
negative consequences of these reactions to themselves or others’ 
(Moeller et al., 2001). Impulsivitiy is often measured in two domains: 
the choice of a smaller, immediate reward over a larger, delayed 
reward (Rachlin & Green, 1972) or the inability to inhibit behavior by 
changing the course of action or to stop a response once it is initiated 
(Logan et al., 1997). Impulsivity is a core deficit in substance abuse 
disorders (Allen et al., 1998). 
Compulsivity 
Defined as elements of behavior that result in perseveration in 
responding in the face of adverse consequences, perseveration in 
responding in the face of incorrect responses in choice situations, or 
persistent re-initiation of habitual acts (Everitt & Robbins, 2005). The 
elements of compulsivity are represented in many of the symptoms 
outlined in the DSM-IV: continued substance use despite knowledge 
of having had a persistent or recurrent physical or psychological 
problem and a great deal of time spent in activities necessary to obtain 
the substance (American Psychiatric Association, 2000). 
Positive 
Reinforcement 
Defined as the process by which presentation of a stimulus, usually 
pleasant (e.g. the drug itself), increases the probability of a response. 
Negative 
Reinforcement 
Defined as the process by which removal of an aversive stimulus (e.g. 
the negative emotional state of drug withdrawal), increases the 
probability of a response (e.g. the dependence-induced drug intake). 
Automaticity 
Defined as behaviors that occur without conscious awareness of 
intentionality. 
Motivation 
Defined as a tendency of the whole animal to produce organized 
activity. 
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Binge and Intoxication 
The Binge and Intoxication phase of addiction is marked by sharp increases in the 
release of dopamine in the reward regions of the brain upon usage of addictive drugs (Di 
Chiara, 2002; Wise, 2008). The increases in dopamine levels cause a reward signal which 
subsequently leads to what is called associative conditioning. Associative learning is 
when the mind makes linkages between the stimuli – drug usage in this context – and the 
reward experiences. Interestingly, it has been observed that with repeated exposures to an 
identical reward, dopamine cells become more responsive to anticipations for the reward 
than the reward itself (Schultz, 2002). These anticipatory urges, which are best 
understood as the cravings one has for a drug, can be induced by environmental stimuli 
such as the setting in which a drug was taken, the people who were present at the time of 
drug usage, and even the psychological state of the person at the time of use (Koob & 
Volkow, 2002). Unlike the drug abuse stage, in the addicted state, drug cravings can be 
induced by these stimuli even long after drug use has ceased, which is indicative of the 
depth to which the conditioned responses are ingrained. 
At the molecular level, the physiological changes are driven by the exogenous 
opioid-induced secretion of DA. These changes, which are broadly termed drug-induced 
neuroplasticity, greatly impact the way in which communication occurs at the synapses 
between neurons and the susceptible reward systems of the brain (Kourrich et al., 2015). 
Further, it has also been shown that drug-induced neuroplasticity also effects learning and 
memory, which is important, when considering that the linkage between experience-
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based learning activities, such as opiate use, can be bolstered by increased signal 
transmission between appropriate circuitries. 
As is true between all synaptic junctions, the strength of signaling can be 
controlled by the density of functional receptors present on the postsynaptic cell. Also, in 
some cases such as for cortical stimulatory neurons, which are involved in activating 
dopaminergic neurons, compositional changes in the subunit of receptors can affect 
signaling by varying the affinity between the neurotransmitter glutamate and its 
respective receptor binding sites (Kauer & Malenka, 2007). Consistent with these facts 
are two receptors – AMPA and NMDA – that are involved in raising levels of DA in the 
NAc. In the animal model studies of Wolf and Ferrario (2010), it was observed that in 
addicted rats, the AMPA receptor had included into its structure a subunit highly 
permeable to calcium called GluR2. The effect of this inclusion was an enhancement in 
the long-term potentiation between neurons. In other words, the modified AMPA 
receptor conferred the release of more copious amounts of DA even in the presence of 
normal amounts of GABA, and furthermore, when an exogenous opioid stimulus was 
introduced even higher levels of DA could be achieved. Expectedly, this change enhances 
the intoxication experienced by the user. In addition to changes in synaptic signaling, 
other studies identified structural changes in neurons of addicted mice, specifically, 
remodeling in dendritic spines and shapes of postsynaptic neurons (De Roo, et al., 2008).  
The ultimate impact of these molecular level changes – which mostly act to 
increase the amounts of DA released – is that in the addicted state, a strong association is 
positively reinforced between drug use and the motivational attribute that compels the 
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addict to want to use again. This learned association becomes so strong that for the 
seasoned addict the craving for opioid is more rewarding than the opioid itself (Schultz, 
2002).  
 
Withdrawal and Negative Affect 
 Of course there are compensatory mechanisms, such as the feedback inhibition 
loop between autoreceptors and VTA dopamine neurons that act to counter intoxication, 
ultimately inducing withdrawal symptoms, but clear abnormalities in this region have yet 
to be outlined. Where there have been notable changes in the neural circuitry is in the 
amygdala, an element of the basal forebrain that is responsible for emotions and survival 
instincts. As is distinct for the Withdrawal and Negative Affect phase of the Addiction 
Cycle, it was shown using an addicted mouse model that there were circuit disturbances 
in the bed nucleus stria terminalis (BNST) – a part of the extended amygdala – and the 
GABAergic projections that innervate postsynaptic VTA neurons that resulted from 
frequent exposures to elevated levels of DA secondary to opioid use (Jennings et al., 
2013). Correspondingly, the results of these changes were that such mice were more 
prone to normalizing the adverse behaviors that induced the negative affect. Also, the 
mice expressing these phenotypes had a propensity to exhibit negative emotions and be 
more sensitive to stress (Jennings et al., 2013). Interestingly, a closer look revealed that 
the drivers of these downstream effects were neurotransmitters that are normally active 
during responses to stress: corticotropin-releasing factor and dynorphin. Just as the 
reward circuitry is hyperactive in the addict’s brain, so too is the “anti-reward” system. 
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Consequently, when the opioids are cleared from the mu receptors, the addict is pushed 
into withdrawal.  
Another fascinating revelation conveyed by studies using mouse models have 
shown that drug consumption triggers significantly smaller increases in dopamine in the 
presence of addiction than in its absence (Zhang et al., 2013). Although the specific 
reason for this attenuated response cannot be traced, it is interesting to note that this 
restricted dopamine release has shown to be impartial to the type of reward, in that the 
addict’s brain becomes less sensitive to broad stimulation as a whole. It is for this reason 
that states of lull and lethargy often accompany addiction, especially in the absence of 
use. Because these changes are not superficially ingrained, the mere stoppage of opioid 
use, should it occur, does not reverse them. When considering the synergistic effects of 
the conditioned desire for reward along with the wanting to escape the dysphoria that 
ensues from not replenishing the addicted brain with opioids, it is of no surprise why an 
impulse to use evolves into a compulsion. In psychiatry parlance, this is referred to as 
negative reinforcement. 
 
Preoccupation and Anticipation 
 The modifications that have been linked to the Preoccupation and Anticipation 
phase of addiction occur in the prefrontal cortex. As is the case in the reward system, the 
PFC regions of the brain also experience a decrease in DA signaling. Consequently, 
executive processes are severely, but not necessarily irreversibly, impaired (Goldstein & 
Volkow, 2011; Table 4).  
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Table 4. Processes Associated with the PFC that are Disrupted in Addiction. 
Adapted from (Goldstein & Volkow, 2011). 
 
 
 
 
These changes are thought to occur due to similar kinds of drug induced 
neuroplasticity that is observed to be complicit in the Binge and Intoxication phase. It has 
been observed through the study by Britt and Bonci (2013) that a rewiring of the neuro-
circuitry takes place primarily in the mesolimbic reward circuits as well as in the PFC. 
Specifically, the drug induced synaptic modifications have been observed in glutamate 
signaling (Britt & Bonci, 2013). The abnormal dopamine and glutamate signaling 
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pathways in the PFC have been traced to certain behaviors such as the failure to resist 
urges and also a seeming impossibility to remain abstinent. Even though the negative 
consequences are well understood, the addict is in the harrowing position of following 
through on compulsions with automaticity despite sincere desires to abstain from using 
the drugs. When the addict succumbs yet again to the cravings, she is once again at the 
start of the seemingly endless cycle. 
Aside from the painstakingly clear indications of disease, what is deeply implied 
by this paradigm for addiction is that there exist great potential for treatment, and if not 
that, then ways mitigate the harm caused by opiates. In the following section, the various 
interventions that have been made available today will be explored, followed by an 
evaluation of the impacts select interventions have had on the opioid epidemic.   
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SPECIFIC AIMS 
 
The Specific Aims of this work include: 
1. Comprehensive review of literature to highlight the interventions – that treat or do 
not treat drug addiction as a disease – being employed to address the opioid 
epidemic. 
2. Evaluate the interventions by looking at patient-based clinical trials and meta-
analyses. 
3. Conclusion on the validity of brain disease model for addiction 
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INTERVENTIONS TO CURB THE OPIOID EPIDEMIC 
 
 Certain implications about the attitudes that rule society’s contemporary view of 
addiction can be inferred by the mere task of this thesis to validate the brain disease 
model for addiction. Even in the face of overwhelming amounts of knowledge that have 
been gained over the last few decades through research that has medicalized addiction, 
there still lacks a general consensus about how to treat the issue. Consequently, the drug 
issue has been addressed with a broad range of solutions, each based on its own theory 
about addiction, and each with its own degree of success. Although it would be of great 
interest to inspect and juxtapose all the interventions put forth to address the opioid 
epidemic, only a select few have been chosen based on the availability of data that can be 
used to gauge its impact. For heuristic purposes, the discussion will begin by looking at 
interventions that treat drug addiction as a disease followed by one that does not. After 
this review, the next section will aim at assessing the aspects of each initiative that have 
been successful at curbing the current epidemic by evaluating their impact.  
 
Medication-Assisted Therapies for Opioid Addiction 
  Medication Assisted Therapies (MATs) is a collective term used to refer to the 
three pharmacotherapies currently approved by the Food and Drug Administration (FDA) 
(Table 5). The medications included in this list are: (1) methadone, (2) buprenorphine, 
and (3) naltrexone. Generally speaking, these drugs are utilized to either mitigate the 
effects induced by opioids or simply prevent them. What all three therapies have in 
common is their mode of action: through the binding of mu opioid receptors, to which the 
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opioids themselves attach. However, what causes the different responses to their binding 
is the way in which each compound stimulates the receptor. As will be shown in the 
following sections, these nuanced differences are what confer MATs their effectiveness 
in treating the eclectic symptoms of opioid addiction. 
 
Table 5. Characteristics of Medications for Opioid-Addiction Treatment. Taken 
from (Volkow et al., 2014). 
 
 
 
 
Methadone 
 Of the three approved treatments for opioid addiction, methadone has been 
utilized for the longest period of time. When it was first synthesized by German chemists 
in the late 1930s, it was described to induce the same subjective effects as morphine, 
including its ability to induce euphoria like most opioids (Freedman & Senay, 1973). 
This is because the active form of methadone is an opioid. However, unlike most 
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addictive opiates like heroin or pain analgesics such as oxycodone, it is long-acting. What 
this means is that, whereas commonly abused opiates are active for up to several hours, 
methadone lingers in the body for up to days (Kosten & George, 2012). Thus, methadone 
has great potential for being highly effective in lowering relapse rates for addicts since it 
can remain on the mu opioid receptor for longer periods of time. The increased duration 
of binding to the mu receptor also decreases the likeliness that drug craves and 
compulsive uses occur. Further, as observed in the seminal studies of Dole et al. (1966), 
it was shown that methadone also acted much like a buffer, such that even when heroin 
was used after the administration of methadone, the user did not experience the high 
normally associated with its use (Figure 10). 
 
   
 
 
 
 
 
 
Figure 10. The Buffering Effect of Methadone on Heroin Use. When a patient was 
administered regularly occurring doses of methadone, the addict was stabilized in the 
zone of “normal function.” Even with the concomitant use of heroin – indicated by the H 
on the plot above – methadone imposed a buffer-like effect on the user’s functional state 
Figure taken from (Dole et al., 1966).  
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 In brain imaging studies that looked at the effect of methadone on opioid receptor 
binding, it was seen that regional variations were observed in a few areas of the brain like 
the amygdala (Kling et al., 2000). These changes were observed with positron emission 
tomography (PET) by looking at the ability of [
18
F]cyclofoxy, an opioid antagonist for 
the mu opioid receptor, to link to the receptors in various regions of the brain. The results 
of this experiment are shown in Table 6 and Figure 11. As a whole, what is indicated by 
the data is that the specific binding of [
18
F]cyclofoxy was approximately 19 to 32% lower 
for methadone-treat patients than those who were not (Kling et al., 2000). Specifically, in 
select regions that are often altered in opioid addiction, such as the amygdala, the 
difference was more pronounced. The lower binding of [
18
F]cyclofoxy in treated patients 
reflects the steady state binding nature of methadone. This explains then why methadone 
is observed to reverse the hormone-related modifications opioids make by binding to mu 
receptors that are involved in stress circuits. In fact, it was subsequently shown in a study 
reported by Schluger et al. (2001) that methadone could be modulating the cortisol-driven 
stress response. 
 
 
 
 
 
 
 35 
Table 6. Total and Specific [
18
F]cyclofoxy Binding in Different Brain Regions. Table 
taken from (Kling et al., 2000).  
 
 
 
 
 
Figure 11. Specific Binding of [
18
F]cyclofoxy in Various Brain Regions of Patients 
that Did or Did Not Receive Methadone Treatment. Figure taken from (Kling et al. 
2000). 
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 Given that methadone is itself an opioid, it can also cause dependence. As such, it 
is currently labeled as a schedule II controlled substance, and can only be administered in 
controlled clinical settings by specially licensed physicians. Further, as states have 
control over which clinics can offer methadone, there exist geographical barriers to its 
access (Figure 15). These regulations, while necessary, have served as impediments to 
opioid-dependent addicts requiring the drug for treatment and also the healthcare 
personnel providing the treatment. Because it is not the case that all addicted patients 
have the means by which to regularly visit clinics to receive treatment, the out-patient 
compliance rate in rural areas has been unimpressive (Fudala et al., 1990). In response to 
these barriers to access, a modified, longer-acting version of methadone called levo-
alpha-acetylmethadol (LAAM) was introduced at the end of the 1990’s. However, it was 
quickly discontinued in 2003 when its usage resulted in heart problems, such as 
ventricular rhythm disorders (Johnson et al., 2000).  
 
Buprenorphine  
 Buprenorphine, unlike methadone, is not a full agonist of the mu opioid receptor. 
Instead, it is what is called a partial agonist: a ligand that binds and activates a receptor, 
but only elicits are diminished response even at full occupancy. Interestingly, however, 
this property yields buprenorphine a duality of functions that manifest at varying doses. 
When present at low concentrations, the drug acts like methadone, and when present at 
high concentrations it can act like an antagonist (Kosten & George, 2012). This 
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phenomenon is called the “ceiling effect” and it is hypothesized to occur due to the 
presence of another sub-type of receptors called opioid-like receptors, also known as 
ORL1 (Ducharme et al., 2012; Walsh et al., 1994; Figure 12). Whereas buprenorphine 
can bind mu opioid receptors as an agonist, its actions by attaching to the ORL1 receptor 
are thought to be antagonistic. This latter behavior is especially evident through its 
mitigating effects when the drug is concomitantly administered with other opioids like 
morphine (Ducharme et al., 2012).  
 
 
 
 
 
Figure 12. The Ceiling Effect of Buprenorphine. Figure taken from (Walsh et al., 
1994). 
 
 
Although buprenorphine is characterized by low activity, due to its high 
specificity and binding affinity for mu opioid receptors, it is more effective than 
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methadone at causing withdrawal in addicts that are dependent on opioids. It has been 
reported in the study by Schuh et al. (1999) that the active form of the partial agonist, 
norbuprenorphine, can remain bound to mu receptors up to five days. Furthermore, the 
low intrinsic activity of the medication confers a normalizing, as opposed to an 
intoxicating, effect on opioid addict patients who are administered the drug during the 
withdrawal phase (Blom et al., 1987). Still, however, there are some side effects that 
accompany buprenorphine; these include: nausea, constipation and sedation. Despite 
these unfavorable reactions, when weighed against other therapies that possess greater 
intrinsic activity, buprenorphine is considered to be safer since it does not induce 
respiratory depression, even at high doses. In fact, a population cross-sectional study that 
juxtaposed the safeties of buprenorphine and methadone use reported that mortality was 
more greatly associated with the latter than the former (Connock et al., 2007). 
Notwithstanding this fact, buprenorphine can still be abused. When users of 
buprenorphine, especially those with non-medical intentions, are misinformed about the 
drug, the drug is taken at very high doses along with other opioids that may provide the 
euphoria generally expected from taking opiates. When taken with benzodiazepines or 
alcohol, buprenorphine is capable of causing respiratory depression followed by inducing 
states of sedation, comatose, and even death (Mégrbane et al., 2006). Further, intravenous 
misuse – which is possible since buprenorphine used to be provided as a tablet – is 
reported to also take place. Although there was no implicit danger from this kind of 
misuse given the drug’s milder effects, the needle delivery method imposed the risks of 
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transmitting various infectious diseases like hepatitis C and HIV (Whelan & Remski, 
2012). 
In response to potential abuse, today, buprenorphine is co-administered with 
another substance called naloxone. Naloxone is an opioid receptor antagonist that 
prevents the binding of opioids to mu receptors. The two drugs have been combined – 
four parts buprenorphine to one part naloxone – to form a pill that is referred to as 
suboxone. Suboxone is designed for sublingual delivery, but given naloxone’s poor 
bioavailability in the oral tract due to its higher hydrophilicity, the effects of 
buprenorphine shadow those of naloxone (Chiang & Hawks, 2003; Figure 13). 
 
 
 
Figure 13. Time Course of Plasma Levels of Buprenorphine and Naloxone after 
Administration of Sublingual Suboxone. Figure taken from (Chiang & Hawks, 2003). 
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Still, suboxone has proven to be quite effective, if not more effective than buprenorphine 
alone given its even lower abuse potential. Even when suboxone was subjected to 
diversion, via intravenous or subcutaneous uses, the major event that ensued was 
withdrawal among opioid dependent addicts (Whelan & Remski, 2012). Unlike 
methadone, buprenorphine can be prescribed by physicians to addicts. Thus, there are 
less restrictions to access that may stand in the way of adherence. 
 
Naltrexone 
 Whereas both methadone and buprenorphine are utilized as maintenance therapies 
for opioid dependent addicts, naltrexone is usually administered at the conclusion of the 
detoxification therapy in the absence of therapies including those mentioned above. 
While its specific mode of action, like those of methadone and buprenorphine, is to bind 
mu receptors, it does not propagate the signals for reward upon linkage. This is because 
naltrexone is singularly an antagonist for the mu opioid receptor. In other words, the 
action of this compound is to block and prevent the firing of the dopaminergic reward 
systems that occurs when opioid receptor agonists bind. When administered, naltrexone 
is a powerful drug for thwarting relapse because it is capable of clinging onto mu 
receptors with approximately more than 100 times the affinity of most addictive opioids 
(Kosten & Kleber, 1984). Along with its impressive pharmacokinetics comes a list of 
potent side effects such as abdominal pain and severe dysphoria (Crowley et al., 1985). 
 In spite of these unpleasant side effects, Petrakis et al. (2007) reported that 
patients who have successfully completed 12-week naloxone treatment courses indicated 
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improved depressive symptoms. Although these results have the implications that 
naltrexone, like methadone, may also be activating receptors in the amygdala, neither 
biochemical pathways nor modes of actions have yet been elucidated. 
 The greatest challenge associated with naltrexone administration, especially in the 
oral form, is compliance (Sullivan et al., 2006; Figure 14). Approximately one-third of 
patients enrolled in naloxone treatment regimen stop taking the drug after a mere two 
weeks, and the dropout rate at the eight month mark lingers around 90% (Judd et al., 
1980). Because this medication does not provide the “high” addicts seek, there is little 
incentive for poorly motivated addicts to continue its usage. The consequence of this is a 
very high likelihood of opioid-overdose mortality due to a relapse accompanied by high 
dosed abuse.  
 
 
Figure 14. Oral Naltrexone Refills, 2000-2002. Figure taken from (Gastfriend, 2011). 
 
 
 In response to this predicament, an extended-release intramuscular version of 
naltrexone called Vivitrol or XR-NTX was released in 2010. Compared to the daily 
intake required by the previous tablet version of naltrexone, the longer-acting injectable 
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drug only needs to be administered once every four weeks at a dosage of 380 mg 
(Harrison et al., 2006).  
 
 
Abstinence-Based Treatment for Opioid Addiction 
 
 If there could exist an antagonist to the aforementioned therapies, it would be the 
concept of abstinence-based therapy for drug addiction, a model for treatment that does 
not condone the use of medication, but instead a following of a strict sets of rules. 
Although many versions of abstinence-based treatments have sprung up since the idea 
was first conceived – and largely endorsed as the standard for addiction recovery – in the 
1930s, they all have been adaptations of what have famously become known as the “12 
Step Recovery Program” (Flanagin, 2014). For reference, the 12 Steps from Narcotics 
Anonymous have been listed in Table 7 below. 
 
Table 7. 12 Concepts for Narcotics Anonymous Service. Adapted from (Narcotics 
Anonymous, 1991). 
 
1. To fulfill our fellowship’s primary purpose, the Narcotics Anonymous groups 
have joined together to create a structure which develops, coordinates, and 
maintains services on behalf of Narcotics Anonymous as a whole. 
2. The final responsibility and authority for Narcotics Anonymous services rests 
with the Narcotics Anonymous groups. 
3. The Narcotics Anonymous groups delegate to the service structure the authority 
necessary to fulfill the responsibilities assigned to it. 
4. Effective leadership is highly valued in Narcotics Anonymous. Leadership 
qualities should be carefully considered when selecting trusted servants. 
5. For each responsibility assigned to the service structure, a single point of decision 
and accountability should be clearly defined. 
6. Group conscience is the spiritual means by which we invite a loving God to 
influence our decisions. 
7. All members of a service body bear substantial responsibility for that body’s 
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decisions and should be allowed to fully participate in its decision-making 
processes. 
8. Our service structure depends on the integrity and effectiveness of our 
communications. 
9. All elements of our service structure have the responsibility to carefully consider 
all viewpoints in their decision-making processes. 
10. Any member of a service body can petition that body for the redress of a personal 
grievance, without fear of reprisal. 
11. Narcotics Anonymous funds are to be used to further our primary purpose, and 
must be managed responsibly. 
12. In keeping with the spiritual nature Narcotics Anonymous, our structure should 
always be one of service, never of government. 
  
 
   
12 Step Recovery Program 
 
 Today, the twelve step program is one of the cornerstones of addiction recovery. 
Widely integrated into the curricula of various self-help groups, such as Alcoholics 
Anonymous and Narcotics Anonymous, it has been reported that approximately 9% of 
American adult population have participated in such therapies (Moos & Timko, 2008). In 
the course of attending such programs, members participate in activities that include 
service work, readings of twelve-steps-embodying texts, practice of integrating the steps 
into daily life, the partnering up with sponsors, and the training to become a sponsor. 
While there are variations in the day-to-day occurrences within treatment centers, the 
central means by which sobriety is attained is through the application of the 12 rules and 
partaking in personal conversations with other members who have also suffered with 
addiction. It is hoped that through this sort of connection with other sufferers and 
mentoring from sponsors that recovery, or complete abstinence, is achieved. In this 
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approach, what is implied is that it is the addict who ultimately possesses the will to step 
away from addiction.  
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EVALUATION OF THE INTERVENTIONS 
  
If there was a litmus test to measure the degree of support for abstinence-based 
programs in the United States, it would look like a map that is singly colored. The test 
would be redundant given the overabundance of such programs today; there were 57,905 
registered groups in 2011 (Magura et al., 2013). However, the same test to get a sense of 
the states’ position on medication assisted treatment, and by extension the brain disease 
model for addiction, would be far more colorful, as indicated by Figure 15. 
 
 
Figure 15. States that Provides Medicaid Coverage for Methadone, Buprenorphine, 
and Naloxone. Figure taken from (Rinaldo & Rinaldo, 2013).  
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In this section the efficacies of the various interventions reviewed in the previous 
section will be gauged by presenting the results of studies that evaluated the on addicted 
patients. Because each intervention is not aimed at the same specific issues within the 
larger problem, there is no single metric that will be used to establish causal relationships 
between interventions and the status of the current epidemic.   
 
Evaluation of Medication Assisted Therapy as Treatment for Drug Addiction 
 On the whole, there is a plethora of scientific evidence that suggests that MATs 
have been immensely successful in treating opioid addiction. For the purpose of 
evaluating their success the different MATs will be assessed using the following metrics: 
(1) degree by which abstinence of drug was achieved, (2) efficacy in reducing opioid use, 
and (3) efficacy in retaining addicts in treatment.  
 
Rates of Abstinence Achievement  
Whether by means of maintenance therapy using methadone or buprenorphine or 
relapse-prevention with extended-release naltrexone, addicts who are enrolled in such 
regimen are shown to double their likelihood of achieving abstinence (Fudala et al., 2003; 
Kruptisky et al., 2011). 
 
Methadone 
 For methadone, it is often noted in clinical studies that the efficacies for achieving 
abstinence is the highest among all agonist based maintenance treatments (Connery, 
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2015). It is for this reason that it still serves as the gold standard against which new 
therapies are held. In the seminal 11-year study that assessed the impact of methadone 
maintenance therapy on abstinence rates, it was reported that of the 161 patients enrolled 
in the treatment regimen, 51 former addicts – about 23% - were completely abstinent at 
the third year post-treatment (Cushman, 1978). More contemporary measurements of 
abstinence, using surrogate quantifications through opioid positive urine analysis, show 
that levels of abstinence levels have remained at similar levels (Johnson et al., 2000; 
Table 8). 
 
Table 8. Outcome Measures of LAAM, Buprenorphine, and Methadone Based 
Maintenance Programs. Taken from (Johnson et al., 2000). 
 
 
 
 In the study it was shown that lower dose methadone treatments exhibited higher 
levels of opioid-positive urinalysis, 79% (p=0.005; 95% CI), than high-dosage 
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methadone, 62% (p=0.005; 95%), suggesting a concentration-dependent efficacy of 
methadone in thwarting relapse (Johnson et al., 2000). A more telling indicator of 
efficacy is portrayed by the primary and secondary outcome measures; high-dose 
methadone and buprenorphine display an increasing trend in continuous abstinence, 
increases of 28% to 38% and 26% to 30% of the patient pools, respectively. Although the 
levels of abstinence conferred by methadone treatments seem fairly low, it is important to 
consider that even 30% abstinent rates is correlated to prevent expenditures of billions of 
dollars and spare tens of thousands of lives (Jackson et al., 2015).  
 
Buprenorphine 
Because there are few prospective cohort studies that have been conducted to 
directly measure rates of abstinence following treatment, another metric used to gauge 
the degree of abstinence, which generally correlates well with abstinence rates is the 
change in craving for drugs over the course of treatment (Figure 17; Table 9). In the 
double-blind trials conducted by Fudala et al. (2003), in which 323 participants were 
given either subutex (just buprenorphine) or suboxone (buprenorphine and naloxone), it 
was shown that both treatment regimen produced earlier and more pronounced decreases 
in the craving when compared to placebo (Figure 16).  
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Figure 16. Time Course of Changes in Opiate Craving. Figure taken from (Fudala et 
al., 2003).  
 
 
Interestingly, the data indicated that significant group-by-week interactions (p<0.001), 
which indicate that the impact of treatment varied with time, were present. Given the 
trend in drug craving over the course of four weeks, this means that the effect of the 
partial agonists was greatest at the start of treatment and gradually waned. Despite the 
tapering effect, the decrease in opioid craving remained non-negligible until the 
completion of the trial. This finding in combination with the urinalysis results for 
buprenorphine shown in Table 8 suggest that it may be this decaying effectiveness of 
suboxone and subutex which lead to a more moderate increasing trend in abstinence 
when compared to methadone. 
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Naltrexone 
 Extended-release naltrexone, also known as vivitrol or XR-NTX, yields similar 
results. In a 24-week double-blind, placebo-controlled, multicenter randomized trial 
involving 250 patients who had histories of opiate addiction, it was shown that XR-NTX 
administration had a significant impact on abstinence rates (Krupitsky et al., 2011; Table 
9). Abstinence was indicated in two ways: (1) through a self-reported timeline follow-
back (TLFB) survey and (2) and through the collection of negative urine drug tests. 
Abstinence was also implicated, as was done for buprenorphine studies, through changes 
in reported cravings for opiates during the course of the treatment period (Figure 17). 
 
Table 9. Clinical Outcomes of XR-NTX. The primary endpoint was marked to be the 
end of the 24 weeks of treatment. Taken from (Krupitsky et al., 2011). 
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Figure 17. Change in Craving During the Course of Treatment with Vivitrol vs. 
Placebo. Blue graph represents placebo. Red graph represents vivitrol. Taken from 
(Krupitsky et al., 2011). 
 
 
According to responses of TLFB surveys, there was a clearly larger proportion of 
participants in the extended-release naltrexone group who remained abstinent, 99.2% 
(p=0.0004), than in those in the placebo group. Although urine analysis findings digress 
slightly from the purported self-reported abstinence levels, nonetheless, at the conclusion 
of 24 weeks of treatment, the percent of weeks that were remained abstinent was 
measured at 90.0% (p=0.0002). In comparison to the placebo group, this indicates that 
XR-NTX treatment had a 55% improvement factor in terms of abstinence (Krupitsky et 
al, 2011). In accordance to expected correlations between abstinence and cravings, 
statistically significant (p=0.0004) reductions in cravings were observed. In a double-
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blind study conducted by Comer et al. (2008), similar results correlating Vivitrol use to 
improved rates of abstinence were recorded. 
Oral naltrexone, an earlier version of Vivitrol that is required to be taken once a 
day given its shorter lasting effects, does not convey similar trends of abstinence. This is 
purported to be because of the difficulty in achieving high levels of adherence to 
regimens based on this drug. The reason for this low compliance, as explained in the 
previous section, is due to it being an antagonist that does not satiate pleasure seeking 
motivation. 
 
Rates of Opioid Use 
 
Methadone 
 In the meta-analysis of several clinical trials conducted by Farré et al. (2002), the 
efficacy of methadone maintenance treatments on the rates of opioid use – the dependent 
variable – was quantified by looking at the odd ratios using a logistic regression. The 
analyses were computed for various comparisons including methadone versus placebo 
and methadone versus buprenorphine. For the former, even the effect of methadone 
dosage was assessed; the results are presented in forest plot below (Figure 18). 
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Figure 18. Pooled Effects of Various Drug Conditions in Comparison with High 
Dose Methadone on Prevention of Illicit Opioid Use. Figure taken from (Farré et al., 
2002). 
 
 
The results depicted in Figure 18 indicate that high doses of methadone, which 
was defined by the study as greater than or equal to 50 mg/day, were far more efficacious 
than lower doses in lowering opioid use: odds ratio – 1.72 (95% CI; p=0.0007). Further, 
compared to placebo, the higher dosages also proved to be better at decreasing abuse 
rates: odds ratio – 2.44 (95% CI; p=0.0033). Consistent, with most other comparisons 
between methadone and buprenorphine, it was also concluded that maintenance 
treatments involving the former were far more successful in this regard than those 
utilizing the latter.  
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Buprenorphine 
In order to detect reduction in the use of opioid while being administered 
buprenorphine, Fudala et al. (2013) conducted a longer open-label study after the double-
blind trials previously discussed. While all the original participants were summoned and 
randomly assigned to subutex and suboxone treatment groups, as was done in the double-
blind studies, this time, treatment courses were extended to between eight weeks to one 
year. Concurrent opioid use was measured through random urine sampling that occurred 
twice a month (Fudula et al., 2013). As depicted in Figure 19, the overall rate of opioid 
use decreased over the course of a year for those on suboxone. Although corresponding 
data for subutex was absent in the report, it is stated that similar trends were observed. 
Further, compared to drug-in-urine analyses that were conducted during the double-blind 
experiments – which were not included in this report – the rate of opioid use in the open-
label studies was significantly lower.   
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Figure 19. Percentage of Urine Samples Negative for Opioids (With Cocaine + 
Benzodiazepines) Through the Duration of Treatment with Suboxone. Figure taken 
from (Fudala et al., 2003). 
 
 
 
As might be expected, there seems to be time-dependent factor in predicting success of 
buprenorphine-based maintenance treatments: the longer patients are administered 
suboxone or subutex, the higher the likelihood they will cease concomitant usage of other 
opioids. Another outstanding finding is conveyed by the data presented in Figure 18. Just 
as was true for methadone, there seems to be also be an inverted correlation between 
concentration of buprenorphine and opioid abuse probability, as indicated by the odds 
ratio from the comparison of high buprenorphine and high methadone: odds ratio – 1.08 
(95% CI; p=0.68) (Farré et al., 2002). 
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Naltrexone 
At the conclusion of 24-weeks of extended-release naltrexone treatment, it was 
indicated through urinalysis that number of opioid-free weeks was substantially higher in 
the XR-NTX groups than those receiving either placebo or no treatment (p=0.0002) 
(Krupitsky et al., 2011; Table 9). Of 126 patients in the XR-NTX group, 119 
participants, or approximately 94%, were determined to be opioid free at end conclusion 
of two weeks. At the same time point, the placebo group showed that 96 members out of 
124, or 77%, were drug free. This gap between the two groups was more or less 
consistent through the remainder of the trial (Krupitsky et al., Figure 20). A waning 
effect, similar to the one associated with abstinence achieve rates, of the MATs ability to 
thwart opioid is visible. Nonetheless, it appears that relative effective of MATs to reduce 
opioid use is greater.  
 
 
Figure 20. Proportion of Opioid-Free Participants in XR-NTX Treatment vs. 
Placebo. Figure taken from (Krupitsky et al., 2011). 
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Retention in Treatment 
While the absolute time of retention varies from study to study, and thus may be 
of little value, when the values are juxtaposed to retention rates as they relate to placebo 
and other treatments much can be gleaned about the effectiveness of the therapies. 
 
Methadone 
It was shown that when compared to buprenorphine maintenance treatment, 
methadone based treatments generally enjoyed greater periods of retention, lasting 
approximately 271 days on average, or roughly 231 more days than buprenorphine based 
regimens (Bell et al., 2009). In the meta-analysis conducted by Mattick, et al. (2014), it 
was shown that this trend held even for different dose combinations of methadone and 
buprenorphine (Table 10).   
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Table 10. Forest Plot of Comparison: Flexible Dose Buprenorphine vs. Flexible Dose 
Methadone; Retention in Treatment. MMT = methadone maintenance treatment; BMT 
= buprenorphine maintenance treatment. Taken from (Mattick et. al, 2014).  
 
 
 
Furthermore, the results in the table above also indicate that in both double blind and 
open label studies, the same trend was observed: the rates of retention was found to be 
lower with relative risk values of 0.83 (95% CI) and 0.80 (95% CI), respectively. The 
reason for retention, which correlates well with the data for these drugs in reducing rates 
of opioid use, may be conferred by the greater intrinsic activity associated with 
methadone. In other words, since methadone is a far more potent agonist that provides the 
similar states of euphoria addicts crave, compliance to regimen tends to be higher.  
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Buprenorphine 
Although the Fudala et al. report (2003) on the efficacies of buprenorphine did not 
intend to gauge retention in their treatment regimen, in both open-label and double-blind 
trial studies it was shown that retention was greater than 82% and 74%, respectively. 
Surprisingly, these figures even reflect patients whose participation was suspended due to 
adverse reactions to prolonged suboxone and subutex treatment. A systematic review of 
55 studies of buprenorphine-naloxone therapies that occurred between 2010 and 2014 has 
also reached conclusions that echo the findings of previous studies: compared to placebo, 
suboxone-based treatments yielded substantially higher retention rates at time points 
ranging from three months to up to 12 months (Timko et al., 2016).  
 
Naltrexone 
In regards to retention rates for extended-release naltrexone, the double-blind 
studies by Krupitsky et al. (2011) reported that the median measure of retention equated 
to 168 days for XR-NTX group and 96 days for the placebo group (p = 0.0042). The 
improvement factor attributed by XR-NTX is roughly doubled. Similarly, the works of 
Comer et al. (2008) corroborate the results of these observations by showing robust 
increases in retention rates for patients put on vivitrol-based regimen as opposed to non-
medication based therapies. Interestingly, it was determined that there exists a dose 
dependent correlation between patients retained in the treatment and adherence as 
measured by time (Comer et al., 2008; Figure 21). This has important implications for 
determining proper dosages to administer for maximal benefits.  
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Figure 21. Retention in Treatment by Study Week and Dose-Dependent Treatment 
Group. “Depot Naltrexone” is another term used for extended-release intramuscular 
naltrexone. Figure taken from (Comer et al., 2008). 
 
 
 
Evaluation of Abstinence-based Therapy for Drug Addiction 
To date, there are not a lot of studies that have been conducted to assess the 
impact of abstinence-based therapies such as the 12-step program, and even less so for 
those that specifically deal with opioid abuse. Of the ones that have been published in 
reputable sources, an overwhelming majority deal with alcohol addiction. Although 
alcohol addiction and opiate addiction are by no means the same disease, they have been 
cited to trace similar courses (Degenhardt et al., 2002). Hence, by heeding the 
recommendation from the works of Moos & Timko (2008), the following evaluation will 
explore studies that have challenged the efficacies of abstinence-based treatment in the 
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context of alcoholism. To make for apt comparisons with the medication-based 
treatments, the 12 Step Programs will also be assessed using the following metrics: (1) 
degree by which abstinence of drug was achieved, (2) efficacy in reducing opioid use, 
and (3) efficacy in retaining addicts in treatment. 
  
Rates of Abstinence Achieved 
 Despite the dearth of studies that appear in scientific literature, it is often 
purported that addicts who partake in twelve-step-based therapies for long durations 
enjoy better drug use outcomes than those who opt out (Moos & Timko, 2008). A meta-
analysis conducted by Humphreys et al. (1997) asserts that long-lasting positive 
outcomes from the participation in Alcoholics Anonymous groups were consistently 
found. Specifically, participants that frequented meetings more in the first three years of 
the evaluation period displayed a higher propensity to remain abstinent at eight years 
(Table 11). 
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Table 11. Prediction of Abstinence at Eight Years. Table taken from (Humphreys et 
al., 1997).  
 
  
 
For the data presented above, abstinence – or remission as it is referred to the 
table – was gauged by using a regression. According to the exponentiated b weights, 
Exp(B), for Alcoholics Anonymous meetings, it can be seen that participants who were 
involved in such programs were 1.007 times more likely to be abstinent at the eight year 
mark. Not shown in the data is the trend that depicted a correlation between the intensity 
of participation, quantified by the frequency of attendance, and remission rates 
(Humphreys et al., 1997). In studies conducted by Tonigan et al. (2003), it was similarly 
shown that addicts whose frequency of attendance was higher experienced 
correspondingly increased rates of abstinence in a three-month period. 
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Although these phenomena may be partially driven by selection bias, according to 
subsequent analyses using two-stage sample selection models, it has been concluded that 
the purported bias caused by self-selection actually pales in comparison to actually 
efficacy of Alcoholics Anonymous (Humphreys et al., 1997).  
 
Rates of Drug Usage 
Further, it was also shown using a longitudinal study that drug usage decreased 
for members who reported attended 12-step program meetings (Gossop et al., 2003). The 
general trend appears to be that longer and more consistent attendance correlates to less 
relapse. Among 150 alcohol-dependent participants in the study, the number of members 
who reported drinking “in the month prior” dropped from 148 (99%) at the start of the 
trial to 84 (70%) at the half-year point. Furthermore, it was recorded that approximately 
51% of the cohort reported drinking on a less frequent basis, and that 70% had reduced 
their daily intake of alcohol. This decrease in substance abuse was also depicted by 
counting the number of times alcohol was consumed on a per monthly basis (Table 12). 
In the month prior to the start of abstinence based therapy, the participants were drinking 
on average 29 days a month. At the conclusion of six months, this number decreased to 
roughly17 times per month. 
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Table 12. Changes in Alcohol Consumption Post-6 Months of Participation in 
Alcoholics Anonymous. Taken from (Gossop et al., 2003). 
 
 
 
 
 In regards to the frequency of participation in a 12-step program, it was noted 
that, in general, addicts who were actively attending – defined as at least once a week –
displayed lower abuse rates of alcohol. This correlation was bolstered by controlling for 
confounding variables such as the duration of meetings (Fiorentine, 1999; Ouimette et al., 
1998).  
 
Retention in Treatment 
 It is immensely difficult to gauge retention to 12-step programs given the 
discrepancies reported by groups such as Alcoholics Anonymous and Narcotics 
Anonymous and those determined from case reports. For instance, in his study of long-
term recovery from alcoholism, Chappel (1993) cites that the retention rate for the first 
three months of participation is approximately 50%. Comparably, the Alcoholics 
Anonymous organization also self-proclaims that year-long attendance amongst its most 
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avid members, a term that is undefined, runs as high as 75% (Orrok, 1976). While these 
levels of retention are remarkably high and quite promising, some doubt is cast by the 
recently measured rates of retention in both Alcoholics Anonymous and Narcotics 
Anonymous groups, in the study by Gossop et al. (2008) (Table 13).  
 
Table 13. Retention Rate at One, Two, and Four-Five Years Follow Up. NA: 
Narcotics Anonymous; AA: Alcoholics Anonymous. Table taken from (Gossop et al., 
2008).  
 
 
 
 
 
Contrary to the findings of the earlier studies, only 17% of original attendees were 
retained in Alcoholics Anonymous meetings at the one year mark (Gossop et al., 2008). 
Subsequent measures that were conducted at two years and also at the four-five year 
points showed decreasing retention trends that were around 10%. The similar downward 
change in participation was also seen in the Narcotics Anonymous groups. The 
discrepancy which portrayed retention rates for the Narcotics Anonymous group to be 
generally higher than those of Alcoholics Anonymous cannot be explained, and is not 
thought to project an implication about the relative needs of one group over the other. 
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Results from a previous study conducted by Gossop et al. (2003) also corroborate these 
findings: only 15% of 150 participants reaped the benefits associated with Alcoholics 
Anonymous attendance. Given the wide discrepancy of retention rates, it is not apt to 
draw any meaning conclusion about the success of abstinence-based programs in 
retaining their participants.   
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CONCLUSION - THE VALIDITY OF THE BRAIN DISEASE MODEL FOR 
DRUG ADDICTION 
 
Government policies, which have a great clout over how healthcare is practiced, 
are great litmus tests for gauging the overarching attitudes toward drug addiction. The 
passage of the Data Addiction Treatment Act of 2000, which for the first time in almost 
80 years allowed for the expansion of pharmacotherapies to be used for opioid addiction, 
is one of the great indicators of forward movement (Merrill, 2002). Also, the 2008 
Mental Health Parity and Addiction Equity Act (MHPAEA) of the Affordable Care Act 
(ACA), which requires insurance companies to raise the standards of coverage for mental 
health or substance-use disorders to the same level as general medical care, is another 
step that drives positive change by appropriating the resources necessary to combat the 
addiction problem (Volkow et al., 2014). These sorts of policies have served as gateways 
into an era of innovation in which new methods corroborated by empirically measured 
success can be utilized to revolutionize drug addiction treatment. However, in order to 
continue pushing toward progress, access to the approved treatments must also be 
improved. As depicted in Figure 16, not all states have equal access to the MATs. When 
this data is overlapped with the drug overdose-related deaths in states, it is noted that the 
some of the states that do not offer coverage for all three FDA-approved MATs also have 
the highest rates of mortalities (Appendix I). Conversely, many of the states that hold a 
more receptive position toward medicalized treatment enjoy lower rates of drug-related 
mortalities.  
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In the process of validating the brain disease model for addiction, it was not the 
goal to disenfranchise abstinence based therapies. Were that even the intention, such 
devaluation could not have occurred given that each individual treatment evaluated 
showed meager success under efficacy tests. That is, a single intervention alone would 
not substantially dent the current opioid epidemic. Hence, the soundest conclusion that 
can be drawn from the reviews is that it is immensely complex. Just as the drug addict 
can embody a person of any race or socioeconomic status, the addiction itself – even to 
the same drug – can exist in several forms with each one paired to its own remedy. To 
this end, the various therapies should not be thought of as competing treatments, but 
rather modalities of treatment that can coexist and supplement one another. As 
substantiated by numerous studies, therapies that combine psychosocial and agonist 
maintenance treatments are far more effective in treating opioid dependence (Amato et 
al., 2011; Amato et al., 2008).. 
Although research has validated the disease model for addiction, as evident by the 
limitations of current treatments, both medical and non-medical, and the current status in 
the fight against opioid epidemic, there is still ample room for improvement. Influenced 
by the broad push in cancer medicine for individualized treatment, an area of growing 
interest for many research clinicians is the concept of personalized addiction treatment 
(Oslin, 2011). Given the multidimensional nature of addiction, such a therapy would 
most certainly be even more efficacious than currently existing standardized protocols for 
treating drug dependence. 
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APPENDIX I – DRUG OVERDOSE DEATHS PER STATE 
 
 
Table taken from (Rudd et al., 2016). 
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RESEARCH EXPERIENCE 
Department of Chemistry: 
Organic chemistry research - Propargyl functional group transfers using metal catalysts 
(2008-2009). 
Research Advisor: Masato Koreeda, Ph.D. 
 
Department of Pediatrics/Hematology: 
Design of zinc fingers that target specific genes in the coagulation cascade. Knock-out 
zebrafish screened chemically to identify modifier genes (2011). 
Research Advisor: Jordan Shavit, M.D., Ph.D. 
 
EMPLOYMENT 
University of Michigan: Science Learning Center (January 2009 — May 2009) 
 Study Group Leader for CHEMISTRY 215 and CHEMISTRY 215HH 
o As a study group leader, I was required to design learning environments, 
in which, instead of teaching, I facilitated rich, scientific discourse 
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amongst students. The greatest value of this experience stems from all that 
came out of working alongside other students – learning to effectively 
assess and address needs.  
 
Life Science Institute (January 2010 — December 2010) 
 Research Assistant 
o I performed basic cloning techniques. I had my first hands on experience 
working with zebrafish and learned to breed them and properly handle 
them. 
 
VOLUNTEER EXPERIENCE 
Ti Kay Haiti (2014 - present) 
o Clinical volunteer at the General Hospital (Port-au-Prince, Haiti Jan. – June 2014) 
o Grant writing and fundraising (July 2014 - present) 
UMHS (2009-2010) 
o Through this experience I was able to work with diverse groups of patients at the 
C.S. Mott Children's Hospital as well as in the 6C pulmonary department.  I was 
able to take part in rich interactions with patients as well as the hospital staff, 
which included nurses, residents, and doctors 
Uganda (2009) 
o I was able to partake in a wide range of activities spanning from helping to set up 
a computer lab, writing letters to President Museveni asking for more educational 
funds, to drawing blood from young children to check for malaria. Although I was 
able to gain clinical experience during the trip, the most valuable part was being 
introduced to poverty and the challenges it poses on health deliverance in 
resource-limited settings. 
 
EXTRACURRICULAR ACTIVITIES 
Harvard-MIT Health Sciences & Technology – HST.936 Global Health Informatics 
Course (2015-present) 
o I enrolled in this free course offered by the Health Science and Technology 
division of the Harvard and MIT consortium to further my education of global 
health practices. Through the course of this term, I will have the opportunity to 
learn alongside students from various disciplines and contribute to ongoing global 
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health projects directed at driving quality improvement through the use of 
informatics and mobile technologies. 
Boston Student Health Activist Community (2014-present) 
o As a member of this organization, I have found opportunities to explore and learn 
about the various local issues that are of concern to students. The Boston Student 
Health Activist Conference, which was held on October 4
th
, 2014, was an 
excellent venue at which students from eclectic backgrounds gathered to discuss 
issues such as Massachusetts’s push for a single payer health care system and 
improving health care for incarcerated patients 
DeveloMaps (2011-2014) 
o I co-founded an internet web tool that has facilitated the process.  Develomaps is 
a website that I designed to help volunteers find projects and organizations 
connect and collaborate.  Develomaps’ main feature is a map that pinpoints the 
locations of projects launched by organizations.  In its functional form, the site 
served as a database from which users accessed up-to-date information about 
specific projects as well as a network in which users can connect. 
Dialogue for Development (2011-2013) 
o Following my trip to Uganda, I co-founded the organization, “Dialogue for 
Development.”  The group’s mission is to create spaces in which students can 
enhance their understanding of the challenges of development.  A major project I 
have led through my participation was organizing the “Good Development 
Conference.”  
 
  
LEADERSHIP 
o Project Manager for Ti Kay Haiti (2014-present) 
o Dialogue for Development (2011-2013 
o Organization co-founder; executive board 
o Good Development Conference Director (April 7, 2012) 
o Bursley Hall Council Co-advisor (2010-2011) 
o Residential Advisor (2010-2011) 
o Bursley Residential Hall 
o Leader for CHEMISTRY 215 & 215HH 
 
